Effects of a humanized CD47 antibody and recombinant SIRPα proteins on triple negative breast carcinoma stem cells

Effects of a humanized CD47 antibody and recombinant SIRPα proteins on triple negative breast carcinoma stem cells

Sukhbir Kaur1,*, Bianca Reginauld1, Sam Razjooyan1, Trung Phi 1, Satya P. Singh3, Thomas J. Meyer2, Margaret C. Cam2, David D. Roberts1,*

1                         Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD USA [e-mail]; [e-mail]; [e-mail]; [e-mail]; [e-mail]

2                         CCR Collaborative Bioinformatics, Resource, Office of Science and Technology Resources, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. [e-mail]; [e-mail]

3                         Inflammation Biology Section, Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA. [e-mail]

* Correspondence: [e-mail] (SK); [e-mail] (DDR)

ORCID ID:

0000-0002-2481-2981  DR

0000-0003-0513-6225  SK

Datasets corresponding to publication: Effects of a humanized CD47 antibody and recombinant SIRPα proteins on triple negative breast carcinoma stem cells. In Frontiers in Cell and Developmental Biology

This repository contains data to reproduce each figure contained in the manuscript, ‘Effects of a humanized CD47 antibody and recombinant SIRPα proteins on triple negative breast carcinoma stem cells.’

Figure 1:  SIRPα-Fc increased Aldefluor activity in MDA-MB-231 cells

Figure S1: A) Expression of CD47 and SIRP alpha using MDA-MB-231 cells via flow cytometry analysis.

Figure S1C: CG disrupts binding between SIRPα and CD47

Figure S1G: Purity of CD24+high and CD24-low Fractions of cells were determined using anti-CD24 antibody via flow cytometry analysis.